Clinical Trial Details
— Status: Not yet recruiting
Administrative data
NCT number |
NCT06443164 |
Other study ID # |
STUDY00026520 |
Secondary ID |
|
Status |
Not yet recruiting |
Phase |
N/A
|
First received |
|
Last updated |
|
Start date |
June 1, 2024 |
Est. completion date |
January 31, 2025 |
Study information
Verified date |
May 2024 |
Source |
Oregon Health and Science University |
Contact |
Jenna W. Stapleton, PhD |
Phone |
503-418-1980 |
Email |
stapletj[@]ohsu.edu |
Is FDA regulated |
No |
Health authority |
|
Study type |
Interventional
|
Clinical Trial Summary
The primary objective of this study is to examine a single-session, 2-hour group intervention
provided to a population of transgender or gender-diverse patients with chronic pain prior to
gender-affirming surgery, to determine if participants who receive the intervention have less
pain-related distress compared to participants randomly assigned to the control group.
Description:
The primary objective of this study is to examine a single-session, 2-hour group intervention
provided to a population of transgender and gender-diverse patients with chronic pain prior
to gender-affirming surgery, to determine if participants who receive the intervention have
less pain-related distress compared to participants randomly assigned to the control group.
This study will help extend the research literature on chronic pain experienced by
transgender patients, and specifically will examine if a brief, group intervention is
effective for reducing pain catastrophizing and pain distress prior to surgery.
Safety and effectiveness of the Empowered Relief intervention used in this study has been
demonstrated in multiple clinical trials, but has not been studied yet with this particular
population. The Empowered relief intervention was created by Beth Darnall © Stanford
University.
The hypothesis of this research study is that transgender patients with chronic pain who
receive the group intervention, prior to having a gender-affirming surgery, will have lower
scores on the pain catastrophizing scale after completing the intervention compared to
participants in the control group:
Hypothesis: µ1 <(<=) µ2. The primary endpoint of this study is to test if the mean change in
the score on the Pain Catastrophizing Scale is different between the treatment and the
control group. The secondary endpoint, is to examine if pain severity scores decreased. An
exploratory endpoint, after data collection and analysis is complete, is to run a focus group
with participants who received the intervention to learn more about their experience to
inform future treatment and research. Safety endpoints are that participants will receive
informed consent, which will include learning they may discontinue participation in the study
at any time, as well as procedures for maintaining confidentiality of identifying
information. Each person screened will already be referred to the Transgender Health Program
by a primary care provider and/or mental health provider. If screening indicates that a
person has severe depression or regular thoughts involving suicidal content, then that person
will not be included in the study but instead will be offered resources and highly
recommended to contact their referring provider for additional support.